Meningococcal disease caused by the bacterium Neisseria meningitidis
is a life threatening condition which severely infects the meninges
or the thin lining surrounding the brain and the spinal cord. Five
out of many serogroups of the bacterium are responsible for the
invasive meningococcal disease. These serogroups are predominantly
present only in humans in the dormant state and may eventually cause
the diseased condition due to environmental or immunogenic factors.
The disease is known to be contagious and its consequences can be
fatal within 24 hours from the onset of symptoms. Prevalence of the
serogroups responsible for the disease varies with age, time and
geographical locations. The global market for meningococcal vaccines
was valued at USD 1,537.3 million in 2013 and is expected to reach
USD 4,450.4 million in 2022 at a CAGR of 12.4 % from 2014 - 2022.
The
global meningococcal vaccines market is segmented broadly into
polysaccharide, conjugate, combination and Men B vaccines. These
vaccine types are further segmented into different brands available
in the market. Polysaccharide vaccines is the oldest type available
in market since last three decades. However, the presence and
widespread use of conjugate vaccines has drastically reduced the
incidences of bacterial meningitis due to the prolonged immunity
achieved against the disease-causing serogroups, unlike
polysaccharide vaccines which provide immunity for a very short
period. Combination vaccines against invasive meningococci in
combination with other organisms such as pneumococcal and Haemophilus
influenzae type B are considered as new weapons to fight against two
bacterial infections. This has shown to reduce the number of
injections needed to be administered when compared to their
individual doses.
Recently approved Men B vaccines include Bexsero by Novartis, and
Trumenba by Pfizer. The U.S. FDA approved Bexsero in January 2015 and
Trumenba in October 2014. In January 2013, Novartis received
marketing authorization for Bexsero as the only vaccine against
serogroup B, across the European Union, Canada and Australia, and has
been currently filed for U.S. FDA licensure. The notable pipeline
conjugate vaccine against meningococcal disease includes NmVac4-DT by
JN International Medical Corporation. NmVac4 DT has been developed
against the broad range of (quadrivalent) serogroups A, C, Y and
W-135. Moreover, JN- International claims the vaccine to be animal
component free, which is expected to be the major driver for its
demand post market launch.
Major growth drivers for the global meningococcal vaccines market
include favourable public-private partnerships to support development
of vaccines at low cost, and the medical emergency status of the
disease. Increase in the demand for vaccines and also the number of
people getting immunized has been majorly contributed to the
education and awareness campaigns conducted by manufacturers as well
as non-profit organizations in the developed economies. Government
intervention such as approval of legislations to mandate immunization
programs for school children up to a certain age, and stringent
regulations for Hajj pilgrims and sub-Saharan travellers also
contribute positively to this market due to increased demand for
these vaccines from the non-profit organizations.
Request for
Sample of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1666
Geographically, North America is the largest market in terms of
revenue in 2013. In North America and Europe, due to government
intervention with respect to legislations, immunization programs and
awareness campaigns incidences of meningitis have reduced to a large
extent. According to a report by the U.S. Centers for Disease Control
and Prevention (CDC) 1,000 to 2,600 people contract meningococcal
disease each year in the United States, whereas in Africa, it is
estimated to be 1,000 cases per 100,000 population. Asia Pacific is
expected to be the fastest growing market followed by Rest of the
World (RoW) during the forecast period. Factors driving the market in
this region include the continuous growth in the population base, the
cyclic occurrences of meningococcal disease outbreaks in past and the
rising focus on preventive measure against the dreadful disease. The
onset of recent trends such as enrolment of pharmacists in training
programs conducted by New Zealand Ministry of Health is also
contributing to the market growth.
The key players contributing to the global meningococcal vaccines
market include Sanofi SA, Novartis AG, GSK plc, Pfizer, Inc., Nuron
Biotech, JN International Medical Corporation, Serum Institute of
India Ltd., Baxter International and Biomed Pvt. Ltd.
